Rein Therapeutics, Inc.
RNTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RNTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RNTX
Rein Therapeutics, Inc. (RNTX) is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, LTI-03, for which it is conducting a Phase 2 clinical trial (RENEW) and expects to report initial topline data in the fourth quarter of 2026. The company has no approved products or revenue and has historically funded operations through equity offerings, most recently a $57.5 million public offering in May 2026.
Key risk: No revenue or approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$65.7M
Cash Runway
14.5 moLead Asset
lti-01 (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials · 1 catalyst for Rein Therapeutics, Inc..
Rein Therapeutics, Inc. (RNTX) is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, LTI-03, for which it is conducting a Phase 2 clinical trial (RENEW) and expects to report initial topline data in the fourth quarter of 2026. The company has no approved products or revenue and has historically funded operations through equity offerings, most recently a $57.5 million public offering in May 2026.
- Lead product candidate LTI-03 is in a Phase 2 clinical trial (RENEW) with first patient dosed in March 2026 [sec_mda · as of 2026-03-26].
- Initial interim topline data from the RENEW trial is expected in the fourth quarter of 2026 [sec_mda · as of 2026-03-26].
- Cash, cash equivalents and investments totaled $43.6 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Net loss was $6.4 million for the three months ended June 30, 2026 [sec_mda · as of 2026-08-14].
- Accumulated deficit was $413.5 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
What works
- The company completed a $57.5 million underwritten public offering in May 2026, providing net proceeds of approximately $53.1 million to fund operations [sec_mda · as of 2026-08-14].
- Cash position improved significantly from $3.2 million at December 31, 2025 to $43.6 million at June 30, 2026, extending the operational runway [sec_mda · as of 2026-08-14].
- The RENEW Phase 2 trial is enrolling patients across the U.S., UK, Europe and other jurisdictions, indicating a global development strategy [sec_mda · as of 2026-03-26].
What to weigh
- The company has no approved products and has never generated revenue from product sales [sec_mda · as of 2026-08-14].
- The company has incurred significant operating losses and negative cash flows from operations since inception, with an accumulated deficit of $413.5 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances clinical development [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
LTI-03 Phase 2 trial first patient dosed in March 2026
“In March 2026, we dosed our first patient in the RENEW Phase 2 clinical trial of LTI-03.”
SEC MD&A · March 26, 2026
Interim topline data expected Q4 2026
“We expect to report initial interim topline data on some proportion of patients in the fourth quarter of 2026.”
SEC MD&A · March 26, 2026
Cash position as of June 30, 2026
“As of June 30, 2026, we had $43.6 million in cash, cash equivalents and investments.”
SEC MD&A · August 14, 2026
Accumulated deficit as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $413.5 million.”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · lti-03 — Phase 2 Readout: lti-03 — Initial interim topline data from the RENEW Phase 2 trial of LTI-03 is expected by the end of 2026, which will provide early efficacy and safety signals.
Risks & what to watch (3)›
Key risks
- No revenue or approved products — Company has never generated product revenue and has no approved products, relying entirely on external financing [sec_mda · as of 2026-08-14].
- Clinical development uncertainty — LTI-03 is in Phase 2; failure to demonstrate efficacy or safety could halt development and impair value [sec_mda · as of 2026-03-26].
- Significant accumulated deficit — Accumulated deficit of $413.5 million as of June 30, 2026 reflects years of losses with no near-term revenue expected [sec_mda · as of 2026-08-14].
What to watch
- Initial interim topline data from the RENEW Phase 2 trial of LTI-03 expected in Q4 2026 [sec_mda · as of 2026-03-26].
- Cash burn rate and whether additional financing will be needed after the May 2026 offering proceeds are consumed [sec_mda · as of 2026-08-14].
- Enrollment progress and any updates on the RENEW trial across U.S., UK, Europe and other jurisdictions [sec_mda · as of 2026-03-26].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Rein Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rein Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
14.5 months
D/E 0.20 · 0% dilution
Lead: Phase 2
3 candidates
1 upcoming, next in ~123d
5 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
43
Total value held
$9.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,997,042 | $2.6M |
| bios capital management, lp | 1,982,375 | $2.6M |
| university of texas/texas am investment management co | 511,610 | $665K |
| prosight management, lp | 411,600 | $535K |
| geode capital management, llc | 344,690 | $448K |
| texas capital bank wealth management services inc | 273,625 | $356K |
| gagnon securities llc | 239,520 | $311K |
| senvest management, llc | 230,895 | $300K |
| palogic value management, l.p. | 180,000 | $234K |
| vanguard fiduciary trust co | 154,512 | $201K |
Showing top 10 of 43 institutional holders of Rein Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 1.7%
- Days to cover
- 5.4
- Shares short
- 487,162
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RNTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rein Therapeutics, Inc.?
Rein Therapeutics, Inc. (RNTX) is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, LTI-03, for which it is conducting a Phase 2 clinical trial (RENEW) and expects to report initial topline data in the fourth quarter of 2026. The company has no approved products or revenue and has historically funded operations through equity offerings, most recently a $57.5 million public offering in May 2026.
What is Rein Therapeutics, Inc.'s lead drug candidate?
Rein Therapeutics, Inc.'s most advanced tracked candidate is lti-01 (Phase 2) for Loculated pleural effusion (LPE).
What is Rein Therapeutics, Inc.'s next catalyst?
Rein Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: lti-03" — expected December 31, 2026.
Who is the CEO of Rein Therapeutics, Inc.?
Dr. James Brian Windsor Ph.D. is the chief executive officer of Rein Therapeutics, Inc. (RNTX).
Where is Rein Therapeutics, Inc. headquartered?
Rein Therapeutics, Inc. (RNTX) is headquartered in Austin, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.